Literature DB >> 28986622

Defensins defend against bone loss.

Friedrich C Luft1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28986622     DOI： 10.1007/s00109-017-1597-2

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN： 0946-2716            Impact factor:   4.599


× No keyword cloud information.
  7 in total

Review 1.  Primate defensins.

Authors:  Robert I Lehrer
Journal:  Nat Rev Microbiol       Date:  2004-09       Impact factor: 60.633

Review 2.  Mammalian defensins in the antimicrobial immune response.

Authors:  Michael E Selsted; Andre J Ouellette
Journal:  Nat Immunol       Date:  2005-06       Impact factor: 25.606

3.  Roles of cathelicidin-related antimicrobial peptide in murine osteoclastogenesis.

Authors:  Kanji Horibe; Yuko Nakamichi; Shunsuke Uehara; Midori Nakamura; Masanori Koide; Yasuhiro Kobayashi; Naoyuki Takahashi; Nobuyuki Udagawa
Journal:  Immunology       Date:  2013-11       Impact factor: 7.397

Review 4.  Bone modeling and remodeling: potential as therapeutic targets for the treatment of osteoporosis.

Authors:  Bente Langdahl; Serge Ferrari; David W Dempster
Journal:  Ther Adv Musculoskelet Dis       Date:  2016-10-05       Impact factor: 5.346

5.  The antimicrobial peptide, LL-37, inhibits in vitro osteoclastogenesis.

Authors:  C Supanchart; S Thawanaphong; A Makeudom; J G Bolscher; K Nazmi; U Kornak; S Krisanaprakornkit
Journal:  J Dent Res       Date:  2012-09-13       Impact factor: 6.116

6.  Osteoblasts participate in the innate immunity of the bone by producing human beta defensin-3.

Authors:  D Varoga; C J Wruck; M Tohidnezhad; L Brandenburg; F Paulsen; R Mentlein; A Seekamp; L Besch; T Pufe
Journal:  Histochem Cell Biol       Date:  2008-10-17       Impact factor: 4.304

7.  A 15-amino acid C-terminal peptide of beta-defensin-3 inhibits bone resorption by inhibiting the osteoclast differentiation and disrupting podosome belt formation.

Authors:  Ok-Jin Park; Jiseon Kim; Ki Bum Ahn; Jue Yeon Lee; Yoon-Jeong Park; Kee-Yeon Kum; Cheol-Heui Yun; Seung Hyun Han
Journal:  J Mol Med (Berl)       Date:  2017-09-09       Impact factor: 4.599
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.